A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure.
Studiedetails
Type carcinoma: | NSCLC met mutatie |
---|---|
Stadium: | IIIB-IV |
Mutatie: | EGFR |
Lijn: | 2de lijns na osimertinib |
Site: | Erasmus MC |
Contactgegevens: | long.oncologie@erasmusmc.nl |
Website: |
Inclusiecriteria
- Participant must have histologically or cytologically confirmed, locally advanced or
metastatic, non-squamous NSCLC, characterized at or after the time of locally advanced
metastatic disease diagnosis by either EGFR Exon 19del or Exon 21 L858R mutation - Participant must have progressed on or after osimertinib monotherapy as the most recent
line of treatment. Osimertinib must have been administered as either the first-line
treatment for locally advanced or metastatic disease or in the second-line setting after
prior treatment with first- or second-generation EGFR TKI. - Participant must have at least 1 measurable lesion, according to RECIST v1.1
- A participant with definitively, locally treated brain metastases must be clinically stable
and asymptomatic, with or without low-dose corticosteroid treatment (≤10 mg prednisone
or equivalent), for at least 14 days prior to randomization. - ECOG 0-1
Exclusiecriteria
Participant received prior systemic anticancer therapy in the locally advanced or metastatic setting, or in the adjuvant setting, for the same nonsquamous NSCLC intended for treatment now
Participant received radiotherapy for palliative treatment of NSCLC less than 14
days prior to randomization.
Participant has active brain metastases not definitively treated with local therapy
Participant has known small cell transformation
Participant has uncontrolled tumor-related pain.
Participant has a medical history of ILD, including drug-induced ILD or radiation
pneumonitis
Meer studies
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:
TROPION-LUNG01
2de lijns | stadium IIIb-IV | AGA-positive
Tropion Lung 07
1e lijns | Stadium III/IV
TEIPP
Stadium IV | 2de lijns
ORCHARD
EGFR | 2de lijn | stadium IV
MK-7684A
1ste lijn | Stadium IV
Mariposa
2de lijn | EGFR | stadium IIIIB - IV
KRYSTAL 12
Stadium IV | 2de lijn | KRAS G12C mutatie
KontRASt-06
An open-label Phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) with a PD-L1 expression <1% or a PD-L1 expression ≥1% and an STK11 co-mutation
ImmunoSABR
stadium IV - 1ste, 2de of 3de lijn
GENMAB
2de lijn - stadium IV
EVOKE
2de lijns | Stadium III/IV
Entrectinib
Stadium IIIB-IV | Eerstelijns | ROS1 mutation
Ensure
Eerstelijn | Fase I
DeLLphi-304
2e lijns | Stadium III
CUP/EAP/DAP/DRUP
Lijst van verschillende programma's
CARMEN-LC03
2e/3e lijns | Stadium III/IV